^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BE CAR7 T

    i
    Other names: BE CAR7 T, BE CAR-7, BECAR7, BE752TBCCLCAR7PBL, Base Edited CAR7 T Cells, BE-CAR7
    Associations

    News

    Trials
    Company:
    Great Ormond Street Hospital for Children
    Drug class:
    CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over1year
    Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. (PubMed, N Engl J Med)
    The interim results of this phase 1 study support further investigation of base-edited T cells for patients with relapsed leukemia and indicate the anticipated risks of immunotherapy-related complications. (Funded by the Medical Research Council and others; ISRCTN number, ISRCTN15323014.).
    Journal
    |
    CD52 (CD52 Molecule) • CD7 (CD7 Molecule)
    |
    BE CAR7 T
    over1year
    Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (clinicaltrials.gov)
    P1, N=10, Recruiting, Great Ormond Street Hospital for Children NHS Foundation Trust | Trial completion date: Sep 2024 --> Feb 2025
    Trial completion date
    |
    CD7 (CD7 Molecule)
    |
    BE CAR7 T
    2years
    Single and Combinational Multiplex Base-Edited 'Universal' CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML (ASH 2022)
    Lentiviral transduction and multiplexed base editing to remove TCR, CD52 and the shared AML/T lineage antigen CD7, enabled the generation of universal donor CAR T cells for combinational use. This data demonstrates robust activity of BE-CAR33 alone and in combination with BE-CAR7 against human CD7+CD33+AML in mice and highlights the importance of strategies that ensure complete targeting of leukemic populations.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD33 (CD33 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD52 (CD52 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule)
    |
    KIT mutation
    |
    BE CAR7 T
    2years
    Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal" CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL (ASH 2022)
    Eligible patients receive lymphodepletion with fludarabine (150 mg/sqm), cyclophosphamide (120 mg/kg) and alemtuzumab (1 mg/kg), followed by infusion of 0.2-2.0x106 BE-CAR7 T cells (maximum 5x104/kg TCRαβ T cells). This Phase 1 study aims to treat 10 children in the UK. Conclusion The study has demonstrated the feasibility of manufacturing "off-the-shelf" GMP-compliant base edited CAR7 T cells and is investigating their safety and efficacy against paediatric r/r T-ALL.
    Clinical • P1 data • IO biomarker
    |
    CD52 (CD52 Molecule) • CD7 (CD7 Molecule)
    |
    cyclophosphamide • Campath (alemtuzumab) • fludarabine IV • BE CAR7 T
    over2years
    Study of Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (clinicaltrials.gov)
    P1, N=10, Recruiting, Great Ormond Street Hospital for Children NHS Foundation Trust
    New P1 trial
    |
    CD7 (CD7 Molecule)
    |
    BE CAR7 T